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Function and Distribution of Apolipoprotein A1 in the
Artery Wall Are Markedly Distinct From Those in Plasma
Joseph A. DiDonato, PhD; Ying Huang, PhD; Kulwant S. Aulak, PhD; Orli Even-Or, PhD;
Gary Gerstenecker, PhD; Valentin Gogonea, PhD; Yuping Wu, PhD; Paul L. Fox, PhD;
W.H. Wilson Tang, MD; Edward F. Plow, PhD; Jonathan D. Smith, PhD;
Edward A. Fisher, MD; Stanley L. Hazen, MD, PhD
Background—Prior studies show that apolipoprotein A1 (apoA1) recovered from human atherosclerotic lesions is highly
oxidized. Ex vivo oxidation of apoA1 or high-density lipoprotein (HDL) cross-links apoA1 and impairs lipid binding,
cholesterol efflux, and lecithin-cholesterol acyltransferase activities of the lipoprotein. Remarkably, no studies to date
directly quantify either the function or HDL particle distribution of apoA1 recovered from the human artery wall.
Methods and Results—A monoclonal antibody (10G1.5) was developed that equally recognizes lipid-free and HDLassociated apoA1 in both native and oxidized forms. Examination of homogenates of atherosclerotic plaque–laden
aorta showed >100-fold enrichment of apoA1 compared with normal aorta (P<0.001). Surprisingly, buoyant density
fractionation revealed that only a minority (<3% of total) of apoA1 recovered from either lesions or normal aorta resides
within an HDL-like particle (1.063≤d≤1.21). In contrast, the majority (>90%) of apoA1 within aortic tissue (normal and
lesions) was recovered within the lipoprotein-depleted fraction (d>1.21). Moreover, both lesion and normal artery wall
apoA1 are highly cross-linked (50% to 70% of total), and functional characterization of apoA1 quantitatively recovered
from aorta with the use of monoclonal antibody 10G1.5 showed ≈80% lower cholesterol efflux activity and ≈90% lower
lecithin-cholesterol acyltransferase activity relative to circulating apoA1.
Conclusions—The function and distribution of apoA1 in human aorta are quite distinct from those found in plasma. The
lipoprotein is markedly enriched within atherosclerotic plaque, predominantly lipid-poor, not associated with HDL,
extensively oxidatively cross-linked, and functionally impaired.  

T

he poor performance of several recent clinical trials
targeting elevation of high-density lipoprotein (HDL)
cholesterol1–3 and the recent Mendelian genetic studies questioning a causal link between genetic variants controlling HDL
cholesterol levels and cardiovascular disease risk4 argue for a
reappraisal of our understanding of HDL. Such a reappraisal
demands that we question assumptions about the pathobiology of the lipoprotein, particularly in cases in which direct
investigation is lacking. Much of what is known biologically
about apolipoprotein A1 (apoA1) in human studies comes
from investigations using isolated lipoprotein particles from
the circulation (plasma or serum) with the use of buoyant density ultracentrifugation. As a known exchangeable lipoprotein,
it is widely recognized that the vast majority of apoA1 within
the circulation resides on spherical HDL particles, where it

serves as the major structural protein of a complex macromolecular assembly of lipoprotein particles with defined buoyant
density (1.063≤d≤ 1.21).5 An unproven assumption is that the
numerous biological functions observed with HDL or apoA1
recovered from the circulation will mirror what occurs elsewhere in vivo.
The functional properties of apoA1 and HDL within the
circulation, however, may not faithfully reflect what occurs
within the artery wall. Early studies identified that lipoproteins isolated from the artery wall, particularly low-density
lipoprotein (LDL), undergo assorted alterations including
proteolysis, various oxidative modifications, and lipolysis to
varying extents.6,7 Several years ago, we reported that apoA1

recovered from human atherosclerotic arterial lesions was
selectively targeted for oxidative modification by myeloperoxidase-generated and NO-derived oxidants and that oxidative modification of apoA1 and HDL ex vivo to a comparable
extent resulted in loss of cholesterol efflux activity of the
lipoprotein.8 Parallel functional characterization and mass
spectrometry studies of circulating HDL isolated by buoyant
density ultracentrifugation revealed that higher apoA1 content of oxidative modifications specifically formed by myeloperoxidase- and NO-derived oxidants was associated with
impairment in plasma membrane transporter ATP-binding cassette A1 (ABCA1)–dependent cholesterol efflux function of
the lipoprotein,8 lecithin-cholesteryl acyltransferase (LCAT)
activity, and acquisition of proinflammatory activity.9,10
Similar findings have been replicated by other groups,11,12 and
numerous additional proteomics studies have since mapped
site-specific oxidative modifications to apoA1 recovered from
the human artery wall.13–16 These studies collectively reveal
that apoA1 is extensively oxidatively modified within an
atherosclerotic-laden artery wall, and similar oxidative modifications to the lipoprotein ex vivo are associated with proatherogenic changes in apoA1 function. However, no studies to
date have directly examined the functional properties or the
particle distribution of apoA1 recovered from human artery
wall. The paucity of direct functional characterization studies is likely a result of the significant challenges that exist in
obtaining sufficient quantities of fresh human arterial tissue
for such biochemical and biological studies.
Herein we sought to examine both the distribution and the
functional properties of apoA1 recovered from the human
artery wall. The present studies demonstrate multiple remarkable findings, including direct evidence that the biological
function and HDL particle distribution of apoA1 within both
normal and atherosclerosis-laden human aortic tissues are
markedly distinct from those of circulating apoA1 and HDL.
These studies suggest that the historical focus thus far on circulating HDL cholesterol levels may not adequately reflect the
actual situation with regard to apoA1 function and HDL particle distribution within the artery wall.

Materials and Methods
Materials
D2O was purchased from Cambridge Isotopes, Inc (Andover, MA).
Chelex-100 resin, fatty acid–free bovine serum albumin, and crystalline catalase (from bovine liver; thymol-free) were purchased
from Boehringer-Mannheim (Ridgefield, CT). Sodium phosphate,
H2O2, and NaOCl were purchased from Fisher Chemical Company
(Pittsburgh, PA). Commercial apoA1 antibodies were from Abcam
(Cambridge, MA), Santa Cruz Biotechnologies (South San Francisco,
CA), and Genway/Sigma (St Louis, MO). 1,2-Dimyristoyl-snglycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol4-yl) (NBD-PE) was purchased from Avanti Polar Lipids. All other
materials were purchased from Sigma Chemical Company (St Louis,
MO) except where indicated.

Methods
General Procedures

Circulating HDL and plasma-derived apoA1 (purified) were obtained
from healthy volunteer donors who gave written informed consent,
and the institutional review board of the Cleveland Clinic approved

the study protocol. Mouse studies involving monoclonal antibody
(mAb) generation were performed under protocols approved by the
Institutional Animal Care and Use Committee at the Cleveland Clinic.
Lipoproteins, including HDL and HDL-like particles (1.063≤d≤1.21)
from plasma and tissue homogenates, respectively, were isolated by
sequential buoyant density ultracentrifugation at low salt concentrations with the use of D2O/sucrose.17 Protein concentrations were determined by Markwell modified protein assay with bovine serum albumin
as standard. Human apoA1 used as control for cholesterol efflux and
LCAT activity assays was purified as described.18 Reconstituted HDL
(rHDL) from isolated apoA1 was prepared by the cholate dialysis
method19 with the use of a molar ratio of apoA1:1-palmitoyl-2-oleoylsn-glycero-3-phosphocholine:cholesterol of 1:100:10. HDL particles
were further purified by gel filtration chromatography with the use of a
Sephacryl S300 column (GE Healthcare,Waukesha, WI) on a Bio-Rad
Biologics DuoFlo FPLC (Bio-Rad, Hercules, CA). Myeloperoxidase
(donor: hydrogen peroxide, oxidoreductase, EC 1.11.1.7) was isolated
(final A430/A280 ratio of 0.6) as described,8,13,14 and its concentration was
determined spectrophotometrically (ε430=170 mmol/L−1 cm−1).8,13,14
H2O2 concentrations20 and ─OCl concentrations8,13,14 were each determined spectrophotometrically (ε240=39.4 mol/L−1·cm−1 and ε292=350
mol/L−1·cm−1, respectively) before use. Peroxynitrite (ONOO−) was
purchased from Cayman Chemicals (Ann Arbor, MI) and quantified
spectrophotometrically before use (ε302=1.36 mmol/L−1·cm−1).13,14 All
buffers used were passed through a Chelex-100 column and supplemented with 100 μmol/L diethylenetriaminepentaacetic acid (DTPA)
to remove any trace levels of redox-active metals. All glassware used
was rinsed with 100 μmol/L DTPA, pH 7.4, and then Chelex-100–
treated distilled deionized H2O and baked at 500°C before use. SDSPAGE was performed as described.13

Tissue Collection

Fresh surgical specimens of human aortic tissue were obtained as discarded material both at time of organ harvest from transplant donors
and during valve/aortic arch (“elephant trunk”) replacement surgery.
Tissue was immediately rinsed in ice-cold normal saline until free of
visible blood, submerged in argon-sparged 65 mmol/L sodium phosphate buffer (pH 7.4) supplemented with 100 μmol/L DTPA and 100
μmol/L butylated hydroxytoluene, and stored at −80°C in screw-cap
specimen containers in which head space was purged with argon.
Butylated hydroxytoluene was omitted from buffer in specimens in
which apoA1 was isolated for functional activity assays.

mAb 10G1.5 Generation, Specificity, and Labeling

Hybridoma cell lines were generated by immunizing apoA1−/− mice
with purified delipidated human apoA1 isolated from HDL recovered from healthy donors. Among the positive clones, subclones were
screened until a mAb with desired binding specificity for equal recognition of all forms of apoA1 (see below) was identified. The subclone, mAb 10G1.5, was selected by screening for equal recognition
of lipid-free and lipidated (in rHDL) apoA1 under native conditions,
as well as after oxidation by exposure to multiple different systems
including myeloperoxidase/H2O2/Cl−, myeloperoxidase/H2O2/NO2−,
and CuSO4 (oxidized as outlined below). To produce sufficient levels of 10G1.5 for immunoaffinity purification of apoA1 from arterial tissues, hybridoma clones were injected into pristane-treated
male BALB/c mice (8 weeks of age). Ascites fluid was collected,
precipitated with ammonium sulfate, then bound and eluted from
a protein A/G column (Thermo Scientific Pierce, Rockford, IL) to
purify mouse mAbs. Isotypes of the mAbs were determined with the
mouse mAb isotyping kit (catalog No. 26179, Pierce Rapid Antibody
Isotyping Strips plus Kappa and Lambda–Mouse, Thermo Scientific
Pierce, Rockford, IL).
Specificity of mAb 10G1.5 was tested with the use of apoA1 or
rHDL either in native form or after incubation at 37°C in 60 mmol/L
Na[PO4] buffer (pH 7.4) with multiple different oxidation systems. The
different myeloperoxidase systems consisted of 19 nmol/L myeloperoxidase, 100 µmol/L DTPA, 40 µmol/L H2O2, and either 100 mmol/L
NaCl or 1 mmol/L KBr or 1 mmol/L NaNO2 as indicated. Horseradish
peroxidase (19 nmol/L) was used with 40 µmol/L H2O2. ApoA1 and
rHDL were exposed to myeloperoxidase and horseradish peroxidase

for 90 minutes at 37°C, and the reactions were stopped by addition
of 2 mmol/L methionine and 300 nmol/L catalase. All other oxidation
reactions were performed for 24 hours at 37°C. Final concentrations of
oxidants used were as follows: H2O2, 40 µmol/L; ONOO−, 40 µmol/L;
ONOO−/HCO3−, 40 µmol/L each; CuSO4, 10 µmol/L; CuSO4/H2O2, 10
and 40 µmol/L, respectively; FeCl3, 10 µmol/L; and FeCl3/H2O2, 10
and 40 µmol/L, respectively. ApoA1 or rHDL (prepared from apoA1 or
their various oxidized versions) was coated at 0.5 µg/mL into enzyme
immunoassay plates and probed with 10 ng/mL anti-total apoA1 mAb
10G1.5 at room temperature for 1 hour. For Western blot analyses,
mAb 10G1.5 was IRDye labeled (LI-COR Biosciences, Lincoln NE)
with the use of the LI-COR IRDye 800CW high-molecular kit at a
dye/protein ratio at 4:1 and visualized by infrared imaging. The IRDye
800CW dye bears an N-hydroxysuccinimide ester reactive group that
couples to free amino groups on the antibody, forming a stable conjugate with antibody. Coupling was performed according to the manufacturer’s instructions.

Human ApoA1 Quantification

Human apoA1was quantified by a Food and Drug Administration–
approved apoA1 immunoassay on the Abbott ARCHITECT ci8200
Integrated Analyzer System (Abbott Labs, Abbott Park, IL). All other
apoA1 was quantified by quantitative immunoblot analysis with the
use of mAb 10G1.5 as the detecting antibody, as determined against
a standard curve of known purified apoA1 standard. Immunoreactive
bands were quantified with the use of Image Studio software (version 2, LI-COR) or Image J (version 1.46; http://rsbweb.nih.gov/). All
nascent HDL particles, as well as isolated human HDL2 and HDL3,
were further purified by gel filtration chromatography with the use of
a Sephacryl S300 column (GE Healthcare, Waukesha, WI) on a BioRad Biologics DuoFlo FPLC.

Aortic Tissue Homogenization

Atherosclerotic lesions from aortic tissues were from subjects (n>20)
with an average age of 83±3 years. Normal human aortic tissues were
obtained from transplant donors (n=5) from the Cleveland Clinic and
had an average age of 23±7 years. All tissue homogenization and lipoprotein fractionation procedures were performed within a cold room
to ensure maintaining tissue and sample temperatures <4°C. Frozen
tissue blocks (submerged in 65 mmol/L sodium phosphate buffer,
pH 7.4, under argon, within screw-cap containers) were thawed by
placement of the containers in an ice/water bath. Immediately before
complete thaw, ice-cold Ca2+- and Mg2+-free Chelex-100–treated
PBS supplemented with 100 μmol/L DTPA, pH 7.4, was added to
rinse the tissue 5 times to remove any residual blood from tissue.
The aorta segment was cleaned of adventitial fat and again rinsed
3 times with ice-cold PBS supplemented with 100 µmol/L DTPA.
Wet weigh of the aorta was determined, and the tissue was cut into
small pieces and then suspended in ice-cold Ca2+- and Mg2+-free PBS
supplemented with both 100 μmol/L DTPA (pH 7.4) and a protease
inhibitor cocktail (Sigma-Aldrich, catalog No. P8340), which was
included in all subsequent solutions used for homogenation and lipoprotein isolation. Aortic tissues were homogenized in an ice/water
bath with a motor-driven Brinkmann homogenizer for 30-second
intervals 5 times with 2 minutes of rest between homogenizations.
Care was taken throughout homogenization to maintain a temperature
at or close to 0°C by keeping the homogenization vessel submerged
within slush (ice/water bath). The crude homogenate was centrifuged at low speed of 15 000g for 30 minutes at 0°C, and the pellet was discarded. This low-speed supernatant (lesion homogenate)
was then used for buoyant density isolation of LDL/very-low-density
lipoprotein (VLDL) (d<1.063), HDL (1.063≤d≤1.21), and lipoprotein-depleted (LPD) fractions (d>1.21). Fractions were dialyzed at
4°C 4 times against 4 L of 5 mmol/L ammonium bicarbonate, with
50 µmol/L DTPA (pH 7.4) and 25 µmol/L butylated hydroxytoluene
changed every 4 hours. A last change of buffer was against 4 L of icecold Chelex-100–treated 1× PBS, pH 7.4.

Immunoaffinity Isolation of ApoA1 From Aortic
Tissue Homogenate

Immunoaffinity resin was generated by covalently coupling mAb
10G1.5 to AminoLink Plus (Pierce Chemical, Rockford, IL) resin at

a density of 1.5 mg antibody per milliliter of resin in an amine-free
buffer (PBS, pH 7.4) according to the manufacturer’s instruction.
Reactive non–antibody-bound sites on the resin were blocked with
the addition of excess ethanolamine. The affinity gel was drained,
and antibody concentration in the flow-through was determined to
calculate cross-linking efficiency, which was >90%. The gel was
then rinsed extensively with 1 mol/L TRIS, pH 7.4, and 1 mol/L
NaCl and then equilibrated in 1× PBS, pH 7.4, before use or storage
(0.002% sodium azide was added if stored). Individual 1-time use
affinity columns (1 mL, drained resin) were prepared with immobilized 10G1.5, and artery wall apoA1 was purified from individual
samples of aortic homogenates under conditions that quantitatively
recovered apoA1, as confirmed with the use of Western blot analyses
of column fractions.

LCAT Activity

Human recombinant LCAT was prepared and purified from culture
medium of a CHO cell line (generously provided by John Parks,
Wake Forest University, Winston-Salem, NC) with stable expression
of human LCAT.21 LCAT activity was determined by calculating the
conversion efficiency of [3H]cholesterol to [3H]cholesteryl ester after
lipid extraction of the reaction mixture followed by thin-layer chromatography.22 Fractional cholesterol esterification was calculated as
disintegrations per minute in cholesterol esters divided by disintegrations per minute in cholesterol esters plus free cholesterol. The fractional cholesterol esterification rate was expressed as units of activity
(nanomoles of cholesterol ester formed per hour per nanogram of
LCAT) per microgram apoA1 protein.

Cholesterol Efflux Activity

Cholesterol efflux experiments were performed according to established procedures.23 The cholesterol efflux was calculated as the total
radioactivity in the medium/(medium radioactivity plus cell radioactivity). Results are expressed as a percentage relative to cholesterol
efflux measured with the use of human apoA1 isolated from healthy
donors (n=5) as control.

HDL Imaging

HDL was dual-labeled and incubated with mouse peritoneal macrophages to individually monitor the fate of phospholipid versus
protein components of the particle as follows. Briefly, the protein
component of isolated human HDL was first labeled with Alexa
Fluor 633 reactive dye kit (Molecular Probes, Eugene, OR) according to the manufacturer’s instructions. HDL lipid was next labeled
by first forming a phospholipid film of NBD-PE by evaporation of a
1:4 methanol:chloroform solution overnight under vacuum and then
rehydrating the film with Alexa Fluor 633–labeled HDL in prefiltered PBS and 4 cycles of alternating rounds of sonication at 0ºC
for 1 minute, followed by a 1-minute interval on ice. Dual-labeled
HDL was centrifuge filtered and washed numerous times with PBS
before incubation with macrophages. Thioglycolate-elicited peritoneal macrophages from C57Blk/6J mice were collected and cultured
as described.24 Dual-labeled HDL (125 µg protein per milliliter) was
incubated with cells at 37°C for 1 hour, and then images were captured on a Zeiss LSM 510 Meta confocal microscope.

Proteomic Analyses

To confirm that the protein recovered after immunoaffinity isolation
(with the use of mAb 10G1.5) from normal aortic tissue homogenate was apoA1, the major SDS-PAGE gel bands at molecular
weights 25 and 50 kDa were excised. The samples were first treated
with dithiotheotol/iodoacetamide (Sigma, St Louis, MO) to carbamidomethylate any cysteines in the protein(s), and then proteins
were digested with the use of Mass Spec grade trypsin (Promega,
Madison, WI) at 37°C overnight. Tryptic peptides were loaded onto
an IntegraFrit sample trap (ProteoPep C18, 300 Å, 150 μm×2.5 cm,
New Objective, Woburn, MA) at 1 μL/min with 5% acetonitrile and
0.1% formic acid to desalt the samples. The peptides were subsequently eluted through a column (75 μm×15 cm) packed in-house
with XperTek 218TP, C18, 300 Å pore size, 150 μm particle size
(Cobert Associates, St Louis, MO) at 200 nL/min with the use of
a Proxeon Easy-nLC II system (Thermo Scientific, Waltham, MA)

with a gradient of 5% to 65% acetonitrile, 0.1% formic acid over
120 minutes into a LTQ-Orbitrap Velos mass spectrometer (Thermo
Scientific, Waltham, MA). Peak lists were generated with the use of
Proteome Discoverer 1.1 (Thermo Fischer Scientific, Waltham, MA).
The resulting Unified Search Files (*.srf) were searched against the
Uniprot FASTA of all apolipoproteins and also against a human protein database downloaded from the European Bioinformatic Institute
(release: 2013_02). Modifications used for searches included carbamidomethylated cysteine (fixed), oxidized methionine and tryptophan (variable), 3-chlorotyrosine, and 3-nitrotyrosine (variable).
Only strictly tryptic peptides with a maximum of 2 missed cleavage
sites were allowed in the database searches. Monoisotopic precursor
ions were searched with a tolerance of 100 ppm with 0.8 Da for the
fragment ions on the data obtained from the hybrid LTQ-Orbitrap
Velos mass spectrometer. Unidentified fragment ions in all fragmentation spectra were manually validated with the use of Protein
Prospector (University of California, San Francisco).

Statistical Analysis

Nonparametric statistical methods were used to determine statistical differences attributable to sampling numbers. The Wilcoxon rank
sum test was used for 2-group comparisons, and the Kruskal-Wallis
test was used for multiple-group comparisons (>2 groups). In cases in
which the Kruskal-Wallis test was performed for multiple-group comparisons and found to be significant (P<0.05), multiple-comparison
procedures such as the Dunn test were used for pairwise comparison
between groups and controls. The Wilcoxon rank sum test was also
used for pairwise comparison. Where indicated, the 1-sample robust
Hotelling T2 test was used to determine statistical significance when
enzymatic activity between the control group and experimental group
was compared.

Results
mAb 10G1.5 Recognizes ApoA1 Equally Well in
its Lipid-Free or HDL-Associated, Native, and
Oxidized Forms
We initially sought to accurately quantify and immunoaffinity isolate apoA1 from artery wall tissue homogenate (from
both normal and atherosclerotic lesions). We reasoned that
this would require a sufficiently tight binding antibody that
demonstrated minimal recognition bias between lipidated versus nonlipidated forms of the lipoprotein, as well as oxidized
versus nonoxidatively modified forms. Examination of every
commercially available antibody we could find (both monoclonal and polyclonal) showed significant bias in recognizing
one form or another (typically recognition of oxidized forms
preferentially, and with inadequate affinity). Figure 1A illustrates the biases observed with 3 characteristic commercial
antibodies (2 polyclonal and 1 mouse mAb). Despite equal
mass of protein loaded into adjacent lanes from native versus oxidized apoA1, and HDL versus oxidized HDL, the
commercial antibodies show varied intensity of staining
(eg, commercial antibody 1 shows oxidized HDL>oxidized
apoA1>>apoA1 or HDL; commercial antibody 2 shows
oxidized apoA1>oxidized HDL>>apoA1 or HDL; and
commercial antibody 3 shows oxidized apoA1 or oxidized
HDL>>apoA1 or HDL). We therefore initially sought to
develop a suitable antibody that met our strict apoA1 recognition criteria. Purified delipidated human apoA1 (isolated
from plasma HDL) was injected into several apoa1−/− mice.
After screening >5000 hybridoma clones for their ability to
recognize apoA1 forms equally well, a small number (4) met
our screening program requirements. One mAb, 10G1.5, was

Figure 1. Apolipoprotein A1 (apoA1) or apoA1 in reconstituted
high-density lipoprotein (HDL) was either left untreated or
oxidized at a 5:1 molar ratio of oxidant to apoA1, as described in
Methods. A, Equal amounts of apoA1 were separated on 5% to
15% reducing SDS-PAGE gels, and proteins were transferred to
membranes for Western blot detection with the use of 3 distinct
commercial antibodies (Ab), as indicated, or the monoclonal
antibody (mAb) 10G1.5. Monomeric and multimeric apoA1
immunoreactive bands are apparent, and molecular weight
markers are indicated. B, Demonstration that apoA1-specific
mAb 10G1.5 recognizes all forms of apoA1 (lipid-free and HDL
associated, nonoxidized and oxidized [ox]) equally well. ApoA1
(open bars) or reconstituted HDL (rHDL; filled bars) prepared
from apoA1 or their oxidized versions using the oxidation
systems as indicated were coated at 0.5 µg/mL into ELISA
plates in triplicate and probed with 10 ng/mL anti-apoA1 mAb
10G1.5. ELISA assays were performed as described in Methods.
Reactions were stopped with 0.1 N HCl, and absorbance at 450
nm was determined. HRP indicates horseradish peroxidase;
MPO, myeloperoxidase. C, Lipid-free apoA1, isolated human
plasma HDL, or the sub-HDL populations HDL2 and HDL3
were each loaded (in triplicate for each data point) onto 5%
to 15% reducing SDS-PAGE gels at the indicated amounts,
and then apoA1 was quantified by immunoblot with the use of
mAb 10G1.5, as described in Methods. All values represent the
average of triplicate determinations; error bars indicate SD.

selected on the basis of specific activity of recognition by
ELISA, immunoblot analysis, its ability to immunoprecipitate
apoA1, and the growth characteristics of the hybridoma clone.
Figure 1B illustrates that mAb 10G1.5 recognizes native
apoA1 and apoA1 reconstituted into HDL particles equally
well. Furthermore, mAb 10G1.5 recognizes apoA1 in native
versus oxidized forms equivalently, with the use of a wide variety of oxidation schemes (Figure 1B). We further examined
the ability of mAb 10G1.5 to quantify different concentrations
of purified apoA1 (lipid-poor) versus equivalent amounts of

total apoA1 in either isolated human HDL (total) or the individual HDL subfractions HDL2 or HDL3 (Figure 1C). As
can be seen, mAb 10G1.5 displayed nearly identical ability
to quantify apoA1 in its varied lipid-free and lipidated forms
over a range of masses. On the basis of the observed unbiased
recognition of all apoA1 forms, we refer to this antibody as
“anti-total” apoA1. This mAb was used throughout the studies described below to detect, immunoaffinity purify, and
quantify apoA1 recovered from plasma, atherosclerotic lesion
homogenates, and normal artery wall homogenates.

The Majority of ApoA1 Isolated From Lesions Is
Highly Cross-Linked and Not HDL Associated
The particle distribution of apoA1 within human atherosclerotic lesions has not been reported. We therefore homogenized
human aortic atherosclerotic lesions (n=10 different subjects)
and used sequential buoyant density ultracentrifugation to
initially remove the VLDL/LDL-like fraction (d<1.063) and
then recover both the HDL-like fraction (1.063≤d≤1.21) and
the LPD fraction (density >1.21), as described in Methods.
Samples were first examined on gradient (5% to 15%) SDSPAGE separations with the use of Sypro Ruby Red protein
staining, which shows minimal protein-to-protein differences in staining; equally stains lipoproteins, glycoproteins,
and other difficult-to-stain proteins; and does not interfere
with subsequent mass spectrometry analyses. Visual inspection showed a complex protein mixture, with an unknown
band migrating at ≈27 kDa, the molecular weight of apoA1
(Figure 2A). Western analysis with anti-total apoA1 antibody
(mAb 10G1.5) of a membrane containing transferred proteins from a parallel-run duplicate gel readily detected within
lesion homogenates a band at the molecular weight of the
apoA1 monomer (Figure 2B). Remarkably, the vast majority
of apoA1 within the aortic lesion was observed to be present
not within the HDL-like fraction but rather within the LPD
fraction (Figure 2B). After substantial increase in exposure
of the immunoblot, apoA1 was detected within the HDL-like
particle fraction (Figure 2C). Also notable within the immunoblots were prominent slower migrating forms of immunoreactive apoA1-containing protein bands at molecular weights
of ≈50, ≈75, and ≈100 kDa present in particular within the
starting material (homogenate) and the LPD fraction (d>1.21)
but noticeably diminished in the HDL-like particle fraction
(1.063≤d≤1.21). The sizes of these slower migrating apoA1immunoreactive bands are consistent with the sizes of oxidatively cross-linked dimeric and multimeric apoA1 forms.
Quantification of the distribution of protein and apoA1 forms
recovered within homogenates from multiple distinct human
atherosclerotic plaque–laden aorta (n=10) is shown in Figure 3.
The majority (81.0±5.6%) of the total protein in the lesion
homogenate was found in the LPD fraction, whereas the HDLlike fraction contained only 1.7±0.2% (Figure 3A). Quantitative
analysis of the anti-total apoA1–specific immunoblots indicated
that nearly all of the apoA1 isolated from lesions was lipid-poor
and found within the LPD fraction (d>1.21), where 0.7±0.4
mg apoA1 per gram wet weight of lesion material was recovered (Figure 3B), corresponding to 92.4±4.1% of total apoA1
in the artery wall (Figure 3C). Surprisingly, only a nominal
amount (<3%) of apoA1 within the artery wall (lesions) was

Figure 2. Apolipoprotein A1 (apoA1) from human atherosclerotic
lesions is not located on high-density lipoprotein (HDL)–like
particles and is heavily cross-linked. Proteins in atherosclerotic
lesion homogenate or after buoyant density ultracentrifugation
fractionation into HDL-like particles and lipoprotein-depleted
(LPD) fractions from the indicated density ranges were
separated on 5% to 15% reducing SDS-PAGE gels. A, Sypro
Ruby–stained gel of the indicated protein samples (10 µg)
from homogenate and the indicated density ranges obtained
from different atherosclerotic lesion tissue samples (n=5).
B, Western blot membrane of a duplicate run gel as in A with
2.4, 0.4, and 2.4 µg of homogenate, HDL-like, and LPD fraction
proteins, respectively, probed with anti-total apoA1 monoclonal
antibody (mAb) 10G1.5. C, Overexposure of Western blot in B
to show apoA1 in HDL-like fraction. Monomeric and dimeric
apoA1 immunoreactive bands and molecular weight markers
are indicated.

recovered in the HDL-like particle fraction (Figure 3B and 3C).
Yet another remarkable finding was the abundance of slower
migrating immunoreactive apoA1-containing bands migrating with molecular masses of dimeric, trimeric, and tetrameric
forms of apoA1 within the lesion homogenates. Quantification
of these apoA1-immunoreactive bands revealed that approximately two thirds (66±4%) of apoA1 within lesions was
oxidatively cross-linked, and the cross-linked forms were preferentially present in the LPD fraction (Figure 3D). Proteomics
analyses of anti-total apoA1 (mAb 10G1.5) immunoprecipitated higher-molecular-weight apoA1 forms confirmed that
these bands also were predominately composed of apoA1 (see
below). Total apoA1 present in the aortic tissues reported is

Figure 3. Particle distribution of apolipoprotein A1 (apoA1)
obtained from human atherosclerotic artery wall. A, Percentages
of total protein in starting homogenate and in buoyant density
ultracentrifugation fractions for low-density lipoprotein (LDL)–like,
high-density lipoprotein (HDL)–like, and lipoprotein-depleted
(LPD) fractions determined by bicinchoninic acid protein assay
are indicted. B, ApoA1 (mg) recovered per gram of lesion tissue
(wet weight) in the HDL-like and LPD fractions. C, Percent apoA1
to total apoA1 from atherosclerotic lesion homogenate present
in the HDL-like and LPD fractions. D, Cross-linked apoA1/total
apoA1 within each fraction as a percentage was determined
by quantitative Western blot analysis of apoA1 immunoreactive
bands in Figure 2B and additional blots (not shown). Values were
determined from samples (n=10); error bars represent SD. Mean
values are indicated by a heavy horizontal line. Kruskal-Wallis
test was used in A and D and found to be significant (P=0.0001
and P=0.0003, respectively). Dunn test was used to adjust for
multiple comparisons, and Wilcoxon rank sum test was used in
pairwise comparisons. Actual P values are listed when P<0.05.

actually modestly underestimated because we know that under
the conditions used, ≈15% to 20% of the total apoA1 remains
unrecovered in the “pellet” from the initial tissue homogenate.
This modest loss appeared acceptable because control studies
with repeated homogenization of the pellet and fractionation of
the recovered material revealed, within both crude homogenate
and subsequent buoyant density isolated fractions, banding
patterns and results that were virtually identical to the original
homogenate and fractions on the basis of both protein staining
and Western blot analyses (data not shown).

ApoA1 Is Markedly Enriched in Lesions, and
Normal Aortic Tissue ApoA1 Similarly Is LipidPoor and Highly Cross-Linked
Our initial studies focused on apoA1 within atherosclerotic
lesions. However, given the surprising finding that virtually

all apoA1 within aortic lesions was not on an HDL particle,
and fully two thirds of all apoA1 within lesions was crosslinked, we decided to examine apoA1 within normal aortic
tissue for comparison. Normal aortic tissue was obtained at
time of organ harvest from transplant donors. For illustrative purposes, images of a typical normal aortic specimen
and a typical atherosclerotic plaque–laden aortic specimen
are shown in Figure 4A. Homogenates of normal aortic tissue (n=5) were prepared and fractionated by buoyant density
ultracentrifugation as described in Methods. Fractionation of
protein from normal artery and lesion homogenates on (5% to
15%) gradient reducing SDS-PAGE gels stained with Sypro
Ruby Red for protein revealed that although there are similarities in the protein banding pattern, the pattern is noticeably
different in normal versus lesion homogenates (Figure 4B).
Notably, immunoblot probing with apoA1-specific anti-total
apoA1 (mAb 10G1.5) of parallel SDS-PAGE gels transferred
to membranes showed that compared with lesion-derived
homogenates, there is very little immunoreactive apoA1 in
homogenates prepared from normal aortic tissue (Figure 4C).
Because extremely low levels of apoA1 were observed
within normal artery wall tissue, and especially the HDLlike fraction, an increased protein amount was loaded onto
SDS-PAGE gels to permit visualization by Western blot and
comparison of HDL-like and LPD fractions from the normal
artery wall homogenate (Figure 4D). The majority of protein
in the normal artery wall homogenate was found to be in the
LPD fraction (Figure I in the online-only Data Supplement).
As observed for aortic lesion apoA1, a significant portion of
apoA1 was lipid-poor and recovered within the LPD fraction. Furthermore, there was a high degree of immunoreactive
apoA1 forms in the normal artery wall that migrate at higher
molecular weights, consistent with that of oxidatively crosslinked apoA1 dimer and higher multimeric forms, particularly
within the LPD fraction (Figure 4D).
Quantification of apoA1-specific immunoblots (with
volumes of starting homogenate and density cut fractions
recovered taken into account) revealed that the total apoA1
recovered per gram of wet weight aortic tissue from normal
artery wall was 120-fold less than that recovered from lesionladen aorta (Figure 4E; note log scale for y axis). Remarkably,
the distribution of apoA1 within normal artery resembled those
found in the same fractions from atherosclerotic lesions, with
only 3% of apoA1 being HDL associated and ≈92% of the
total apoA1 present in the normal artery wall residing in the
LPD fraction (Figure 4F). Similar to our observation within
lesions, nearly half (43.4±13.9%) of the total apoA1 within
the normal artery wall was cross-linked and was observed to
reside not on the HDL-like particle (3.6±2.6%) but in the LPD
fraction (61.4±23.0%; Figure 4G).
Because the levels of apoA1 in the normal artery wall–
derived homogenates were so low, we wanted to verify that
the bands detected on Western blots with the use of mAb
10G1.5 were in fact apoA1. We therefore immunopurified
apoA1 from normal aortic tissue homogenates (n=5) using
10G1.5 (as described in Methods), and immunoaffinity isolated proteins were separated on a gradient nonreducing
(5% to 15%) SDS-PAGE gel and stained for protein. The
major protein bands observed corresponded to doublet bands

Figure 4. Apolipoprotein A1 (apoA1) obtained from
the artery wall is not on a high-density lipoprotein
(HDL)–like particle and behaves in a manner
similar to that isolated from atherosclerotic lesions.
A, Representative aortic tissue from normal and
atherosclerotic human artery wall. B, Sypro Ruby–
stained 5% to 15% SDS-PAGE gel of normal and
atherosclerotic lesion homogenate (n=5) proteins
(5 µg). C, Western blot of duplicate gel as in A
with the indicated amount of protein per lane (n=5)
probed with anti-total apoA1 monoclonal antibody
(mAb) 10G1.5. D, Western blot of normal artery
wall proteins (30 µg) from homogenate (sample 1,
pooled samples 2 and 3, and pooled samples 4
and 5), HDL-like, and lipoprotein-depleted (LPD)
fractions probed with anti-total apoA1 mAb 10G1.5
to show apoA1 and cross-linked apoA1. E, ApoA1
(mg) recovered per gram of normal aortic tissue (wet
weight) in the HDL-like and LPD fractions. F, ApoA1
to total apoA1 as a percentage from normal aortic
tissue homogenate present in the HDL-like and LPD
fractions. G, Cross-linked apoA1/total apoA1 within
each fraction as a percentage was determined
by quantitative Western blot analysis of apoA1
immunoreactive bands in C and D. Monomeric
and dimeric apoA1 are indicated. Values were
determined from samples of n=5 (C) and n=3 in
(D) and additional blots (not shown); error bars
represent SD. Mean values are indicated by a heavy
horizontal line. Kruskal-Wallis test was used in G
and found to be significant (P=0.006). Wilcoxon
rank sum test was used in pairwise comparisons to
determine statistical differences. Actual P values are
listed when P<0.05.

migrating at ≈25 and ≈50 kDa (Figure II in the online-only
Data Supplement). These were individually excised and
digested with trypsin for mass spectrometry analyses, as
described in Methods. Tandem mass spectrometry analyses
of tryptic peptides for each excised band revealed apoA1 as
the dominant protein within each, with 40% to 62% peptide
coverage in each of the gel-excised bands (Tables I through
IV in the online-only Data Supplement).

Plasma ApoA1 Is Predominantly HDL Associated
and Has Decreased ApoA1 Cross-Links in the HDLlike Fraction Compared With the LPD Fraction
Given the surprising HDL particle distribution and cross-link
prevalence of apoA1 found in the artery wall (Figures 2–4)
and the known preponderance of apoA1 within the HDL
fraction in plasma, we examined the distribution of apoA1
in plasma using the same anti-total apoA1 mAb (10G1.5).
Plasma from normal healthy consenting donors was fractionated by sequential buoyant density ultracentrifugation as
described in Methods. The indicated amounts of protein from
the starting material plasma, HDL-rich fraction, and LPD

fractions were run on gradient (5% to 15%) reducing SDSPAGE gels and stained with Coomassie Blue (Figure 5A) or
transferred for immunoblot analyses with anti-apoA1 mAb
10G1.5 (Figure 5B). As expected, the dominant immunoreactive band observed migrates at ≈27 kDa, corresponding to the apoA1 monomer, and is predominantly recovered
within the HDL fraction (≈83%; Figure 5B and 5D). Unlike
apoA1 recovered from the artery wall, there is little noticeable
higher-molecular-weight cross-linked apoA1 in the starting
plasma, particularly within the circulating HDL fraction. Of
note, however, the content of apoA1 cross-linked within the
LPD fraction was found to be 3-fold higher than that observed
within the HDL fraction but still represented only a small
minority (6.0±1.8%) of the total apoA1 within that fraction
(Figure 5E; longer exposures of plasma and LPD fractions are
shown in Figure III in the online-only Data Supplement).

ApoA1 Isolated From Atherosclerotic Lesions
Is Dysfunctional
In a final series of experiments, apoA1 was isolated from
additional atherosclerotic plaque–laden aortic tissues (n=10

Figure 5. Apolipoprotein A1 (apoA1) in plasma is on highdensity lipoprotein (HDL) particles and behaves differently
than artery wall–derived apoA1. Plasma from normal healthy
human volunteers (n=5) was fractionated by buoyant density
gradient centrifugation. A, Coomassie Blue–stained 5% to 15%
SDS-PAGE gel of plasma, high-density lipoprotein (HDL), and
lipoprotein-depleted (LPD) fraction proteins. B, Western blot
analysis of proteins on membrane from a duplicate fractionated
protein gel probed with anti-total apoA1 monoclonal antibody
(mAb) 10G1.5 shows apoA1 predominantly in the HDL fraction
and not cross-linked. C, Percentage of total protein recovered
in starting material and in very-low-density lipoprotein
(VLDL)+low-density lipoprotein (LDL), HDL-like, and LPD
fractions. Quantitative analyses of B and overexposed B reveal
percentage of apoA1 to total apoA1 present in the plasma HDL
and LPD fractions in D and cross-linked apoA1/total apoA1
within plasma, HDL, and LPD fractions in E. Values (C and D)
were determined from samples (n=5). Error bars represent SD;
mean is indicated by a heavy horizontal line. Kruskal-Wallis test
was used to determine statistical differences for data presented
in C and E, which were found to be significant (P=0.0002 and
P=0.01, respectively). Dunn test was used to adjust for multiple
comparisons in C, and Wilcoxon rank sum test was then used for
pairwise comparisons. Actual P values are listed.

subjects) by individual immunoaffinity columns composed of
immobilized anti-total apoA1 (mAb 10G1.5), as described in
Methods. Immunoisolated apoA1 was quantified, and equivalent amounts of apoA1 protein were recovered from lesions
from each sample, or apoA1 purified from plasma HDL (as
a control) was incubated with cholesterol-loaded murine
macrophage RAW264.7 cells to quantify cholesterol efflux
activity. Remarkably, every apoA1 sample recovered from
plaque-laden aorta demonstrated lower cholesterol acceptor activity, showing 78.9± 6.0% less total cholesterol efflux
capacity compared with control apoA1 purified from plasma
HDL from healthy donors (Figure 6). In parallel studies, each
of the lesion apoA1 samples was incorporated into reconstituted HDL by cholate dialysis method and further purified
by gel filtration fast protein liquid chromatography, and then
comparable amounts (5 µg apoA1 mass) of each rHDL were
examined for LCAT activity and compared with rHDL generated from apoA1 purified from plasma HDL from healthy
volunteers. rHDL formed with lesion apoA1 demonstrated

Figure 6. Functional characterization of lesion apolipoprotein
A1 (apoA1). Macrophage cholesterol efflux activity and lecithincholesteryl acyltransferase (LCAT) activity were measured in
apoA1 immunoaffinity purified from human atherosclerotic-laden
plaque (n=10 different subjects), as described in Methods. ApoA1
isolated from plasma high-density lipoprotein recovered from
healthy donors (n=3) and reconstituted high-density lipoprotein
formed from these apoA1 particles served as controls for total
efflux activity and LCAT activity, respectively. Bars represent
triplicate determinations; error bars represent SD. P values
represent comparison between subject samples vs control
apoA1 and were determined with the use of the 1-sample robust
Hotelling T2 test.

significantly less (89.6±5.0%) LCAT activity compared with
rHDL formed from control apoA1 (Figure 6). Thus, apoA1
in atherosclerotic plaque–laden aorta is markedly functionally
impaired (ie, “dysfunctional”) with respect to both cholesterol
acceptor and LCAT activities.

Discussion
The present studies reveal multiple remarkable findings about
apoA1 within the artery wall. First, the vast majority of apoA1
within both normal and atherosclerotic human arterial tissue,
in contrast to within the circulation, is lipid-poor (ie, in the
LPD fraction, d>1.21) and does not reside on an HDL-like
(1.063≤d≤1.21) particle. Second, the content of apoA1 in
atherosclerotic lesions is >100-fold higher than that observed
within normal artery wall. Third, the majority of apoA1 within
arterial tissues (both normal and atherosclerotic) is oxidatively
cross-linked. Fourth, apoA1 within arterial tissues is dysfunctional, with ≈80% reduction in cholesterol acceptor activity
and ≈90% reduction in capacity to activate LCAT. Fifth, the
majority of oxidatively cross-linked apoA1 within the circulation is not HDL particle associated but rather resides within
the LPD fraction (d>1.21). Collectively, the present studies
thus argue that examination of total apoA1 and HDL function within the circulation may not adequately represent what
is occurring within the artery wall, especially with respect to
cholesterol acceptor and LCAT activities. Moreover, the overall strategy applied in the present studies may prove useful
in the examination of other posttranslational modifications to
apoA1, such as glycation, and site-specific oxidative modifications as antibodies become available. Finally, the present
studies suggest that the common practice of isolating circulating HDL for study of its biological properties and discarding
the lipid-poor (non–HDL associated) apoA1 may in fact be
throwing out the very fraction (lipid-poor) that more closely

reflects the environment within the artery wall. Of note, the
extent of oxidatively cross-linked apoA1 within the lipid-poor
(LPD) fraction of plasma was ≈3-fold enriched relative to the
HDL-like fraction (Figure 5E). On the basis of the cumulative
results herein, one might speculate that dysfunctional forms of
HDL monitored within the circulation will most likely reside
not on the HDL particle itself but as lipid-poor forms in the
LPD fraction (d>1.21). It is notable that the apoA1 found
within the artery wall, which was predominantly within the
LPD fraction in both atherosclerotic lesions and normal artery
wall tissue, is remarkably highly cross-linked (50% to 70%).
This value is even higher than previously observed in Western
blots (though cross-linking was not quantified per se) in studies examining apoA1 oxidation levels in the artery wall based
on buoyant density recovery of HDL-like particles.8 Through
use of stable isotope dilution mass spectrometry–based
approaches, these studies suggested that an upper boundary of up to 1 of every 2 HDL-like particles recovered from
the artery wall carried an oxidative modification from either
myeloperoxidase- or NO-derived oxidants.8
One question the present studies raise is how apoA1 becomes
>100-fold enriched within atherosclerotic plaques compared
with normal artery. A second question is how artery wall
apoA1 is rendered lipid-poor when the vast majority of apoA1
that diffuses into the artery wall tissue from the circulation
resides within the HDL particle. To address these questions,
we performed preliminary confocal microscopy studies in
which HDL was isolated from peripheral blood of healthy volunteers and subsequently doubly labeled (protein with Alexa
Fluor 633 [red] and phospholipid with NBD-PE [green], as
described in Methods). Brief incubation of the double-labeled
HDL with macrophages led to virtually all of the phospholipid
fluorophore being rapidly taken up within the macrophage,
whereas the protein (predominantly apoA1) remained on the
cell surface (data not shown). Such preliminary results provide a rationale to speculate that selective uptake of lipids may
contribute as a mechanism for rapidly depleting the HDL particle of not just cholesterol but also phospholipid, leaving the
lipid-poor apoA1 behind in the extracellular space. Lipid-poor
or lipid-free forms of apoA1 are recognized as the preferred
substrate of ABCA1.5,25–27 Therefore, a question that logically
follows is why the lipid-poor apoA1 form within the artery
wall is such a poor cholesterol acceptor (Figure 6). In past
studies, we have shown that oxidative modification of apoA1
by myeloperoxidase-generated oxidants markedly impairs
its ABCA1-dependent cholesterol efflux activity.8–10,13 Other
studies have also reported that carboxy-terminal proteolized
(ie, “clipped”) apoA1 can be recovered from aortic tissue
that fails to efficiently bind lipid.28,29 In the present studies,
however, we did not see substantial levels of lower-molecular-weight forms of apoA1 in tissue homogenates once we
exercised extreme care in keeping tissues ice-cold and, more
importantly, included an extensive cocktail of protease inhibitors during tissue dissection, homogenization, and fractionation, as outlined in Methods. Given the extensive oxidative
cross-linking observed in total apoA1 within lesions, oxidative posttranslational modifications of apoA1 likely explain in
large part why the lipoprotein, at least within lesions, remains
lipid-poor. It should also be noted, however, that Parks and

colleagues26 reported that interaction of apoA1 with ABCA1
results in lipid-poor pre-β HDL migrating forms of apoA1 that
themselves are poor substrates for subsequent repeat or further
lipidation by ABCA1, suggesting the requirement of an additional (non–ABCA1-mediated) process for further maturation
into an HDL particle. Whether this contributes to the present
results is unclear. Similarly, if an additional process is needed
for further lipidation of lipid-poor apoA1 after initial interaction with ABCA1, whether this process is somehow lacking
or inhibited within the artery wall requires further study. It
also would have been interesting to test whether rHDL made
with apoA1 isolated from the vessel wall was also defective
in either ABCG1 or passive efflux compared with HDL made
with plasma-derived apoA1. However, given the limitations in
the amount of apoA1 able to be purified from human arterial
tissues, these studies will need to await further investigation.
As for the mechanism(s) for apoA1 accumulation within
lesions compared with normal artery, we have no clear answers
from the present studies. We can speculate that the extensive
oxidative cross-linking noted here may help to provide an
answer, as well as mass spectrometry studies in the past.8–10,13
Oxidatively modified proteins tend to be less soluble and relatively protease resistant and might thus be “retained” within
the subendothelial space, particularly within the hydrophobic
environment of the atherosclerotic plaque. The phenomenon of
lipoprotein retention within the subendothelial compartment
of the artery wall has been suggested previously. Originally
proposed for apoB lipoproteins, retention or trapping of LDL
particles in the initial stages of atherosclerosis is suggested to
cultivate formation of modified LDL, which may incite biological and inflammatory responses that initiate or advance the
atherosclerotic process.30 Progressive apoB lipoprotein retention through the actions of secretory acid sphingomyelinase
and lipoprotein lipase are thought to lead to accelerated lesion
progression.31,32 Although we have no data to implicate lipase
activation at present in depleting lipids from HDL within the
artery wall leading to lipid-depleted forms, the presence of
similar phospholipids on HDL suggests that a similar retention scheme for apoA1 lipoprotein retention is feasible and
could thus contribute to the observed accumulation of apoA1
in artery wall lesions over time, in addition to enhanced lipid
and sterol uptake into macrophages producing foam cells.
Other studies have also shown that increased endothelial cell
permeability in atherosclerotic lesions could lead to increased
LDL and HDL migration into the diseased vessel wall and
accelerate the retention process.33–35
Although multiple studies have noted extensive oxidative
modification of apoA1 recovered from the artery wall,8–11,13–
16,36
there has been disagreement about which residues are
the main sites of oxidation. Our prior proteomic mapping
studies used polyclonal antibodies (chicken anti-apoA1 or
anti-HDL) to immunoprecipitate apoA1 from arterial tissue
homogenates.13,16 In contrast, proteomic mapping studies from
alternative groups typically have used buoyant density isolation to recover the HDL-like particle fraction within lesion
homogenates.11,15 On the basis of the present studies using the
mAb 10G1.5, which was developed specifically to allow both
recovery and equal quantification of apoA1 in lipid-free versus lipidated and native versus oxidized forms, it is now clear

that analysis of recovered HDL-like particles from arterial tissues only examines a very small fraction (<3%) of the total
apoA1 within the artery wall. Whether the small amount of
apoA1 (and its associated proteome) recovered in an HDLlike particle from the artery wall provides a “snapshot” of the
apoA1 on its way to particle “disintegration” and formation
of the lipid-poor apoA1 that is the predominant form remains
to be determined. The present studies suggest that results that
focus on HDL-like particles recovered from the artery wall
need to be interpreted within the context of recognizing their
minor quantitative contribution to total apoA1 in the artery
wall. An interesting question, although not examined in the
present studies, is whether changes in the HDL-associated
proteome within the circulation observed in subjects with cardiovascular disease or within subjects at heightened risk for
cardiovascular disease37–41 have any relevance to the marked
changes in the environment of apoA1 observed within the
artery wall.
The complexity surrounding the role of the HDL particle in the pathogenesis of cardiovascular disease has been
highlighted recently because of several high-profile clinical
trial failures targeting raising of HDL cholesterol and recent
Mendelian randomization studies on HDL cholesterol levels.1,2,4,42–47 The present studies suggest that traditional HDLmeasured parameters within the circulation, such as HDL
cholesterol and apoA1 mass, may not adequately reflect the
biology of apoA1 occurring within the artery wall. Recent
studies suggest that functional measures of cholesterol
efflux activity within apolipoprotein B–depleted serum may
serve as a superior surrogate for HDL function.48 However,
this too has recently been questioned because the HDL
particle was found to account for only a minority of the
cholesterol acceptor activity in the cholesterol efflux activity assays performed.49 Furthermore, despite the reported
inverse association between cholesterol efflux activity and
prevalent cardiovascular disease, in a separate large clinical
study of similar patients (ie, sequential subjects undergoing
elective diagnostic coronary angiography), enhanced cholesterol efflux activity was observed to be associated paradoxically with increased prospective cardiovascular event
risk.49 It is remarkable that what we now recognize as HDL
was first described nearly a century ago.50 Yet, studies focusing on HDL still continue to surprise us and reveal how little
we know about its complex biology. The present and recent
studies suggest that measurement in the circulation of HDL
cholesterol, apoA1, or even cholesterol efflux activity may
not adequately reflect what is happening within the artery
wall. Rather, development of dysfunctional HDL assays that
detect structurally specific modified forms of apoA1 formed
in the artery wall but that diffuse back out into the circulation may be what is needed to provide insights into the
processes occurring within the artery wall.
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